Lineage Cell Therapeutics In (LCTX) — 13F Holders Deep Dive (Q2 2026)

LCTX ranks #3946 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

LCTX is a top-conviction position for Raffles Associates LP — at 5.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in LCTX belongs to Broadwood Capital Inc, but the position matters far more to Raffles Associates LP, who has 5.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

State Street has added to its LCTX position for two straight quarters, increasing it by $1.3M to reach $3.0M today.

Broadwood Capital Inc has trimmed its LCTX position for two straight quarters, cutting it by $17.8M while still holding $64.9M.

LCTX is up 2.8% today, and institutions have been net buyers of $15.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

LCTX reported a net loss of $32.3M over the trailing twelve months.

• Not yet profitable — net loss of $32.3M over the trailing twelve months
• Revenue grew 19.9% year over year
• Net income improved year over year, from -$40.9M to -$32.3M
• Operating cash flow was negative, using $18.9M in cash
• Current ratio of 5.20x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.55x equity — within a conventional range